New combo therapy aims to tame stem cell transplant complications
NCT ID NCT05120570
First seen Jan 06, 2026 · Last updated Jun 20, 2026 · Updated 25 times
Summary
This study tested a new drug called VIC-1911 added to standard medications to prevent graft-versus-host disease (GVHD) in 16 adults with blood cancers receiving a stem cell transplant. The goal was to find a safe and effective dose that reduces GVHD and relapse. Results are still being analyzed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VIC-1911
What this could lead to
If successful, this could lead to a safer stem cell transplant with less risk of graft-versus-host disease and relapse.
What could go wrong
This is an early-phase trial with only 16 participants, so results may not apply broadly. The drug may cause side effects or not work as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.